Elżbieta Grześk

Dr. Elżbieta Grześk

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ŁWŁukasz Wołowiec
Łukasz Wołowiec
JOJoanna Osiak
Joanna Osiak
AWAnna Wołowiec
Anna Wołowiec
AWAleksandra Wijata
Aleksandra Wijata
EGElżbieta Grześk
Elżbieta Grześk
GGGrzegorz Grześk
Grzegorz Grześk
Dyslipidemia is listed among important cardiovascular disease risk factors. Treating lipid disorders is difficult, and achieving desirable levels of LDL-cholesterol (LDL-C) is essential in both the secondary and primary prevention of cardiovascular disease. For many years, statins became the basis of lipid-lowering therapy. Nevertheless, these drugs are often insufficient due to their side effects and restrictive criteria for achieving the recommended LDL-C values. Even the addition of other drugs, i.e., ezetimibe, does not help one achieve the target LDL-C. The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) discovery has triggered intensive research on a new class of protein-based drugs. The protein PCSK9 is located mainly in hepatocytes and is involved in the metabolism of LDL-C. In the beginning, antibodies against the PCSK9 protein, such as evolocumab, were invented. The next step was inclisiran. Inclisiran is a small interfering RNA (siRNA) that inhibits the expression of PCSK9 by binding specifically to the mRNA precursor of PCSK9 protein and causing its degradation. It has been noticed in recent years that siRNA is a powerful tool for biomedical research and drug discovery. The purpose of this work is to summarize the molecular mechanisms, pharmacokinetics, pharmacodynamics of inclisiran and to review the latest research.

19 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GGGrzegorz Grześk
Grzegorz Grześk
WSWioleta Stolarek
Wioleta Stolarek
MKMichal Kasprzak
Michal Kasprzak
EGElżbieta Grześk
Elżbieta Grześk
DRDaniel Rogowicz
Daniel Rogowicz
MKMarek Krzyżanowski
Marek Krzyżanowski
Background: Carbamazepine (CBZ) is a first-generation anticonvulsant drug. Hence, in certain cases, therapeutic drug monitoring (TDM) supports pharmacotherapy. Methods: The presented research was based on a retrospective analysis including 710 ambulatory and hospitalized patients treated with CBZ between the years 1991 and 2011. The method used for the determination of the CBZ concentration was fluorescence polarization immunoassay (FPIA) performed using an Abbott GmbH TDx automatic analyzer, with the therapeutic range for carbamazepine being 4–12 µg/mL. Results: The therapeutic range was observed more often in patients between 3 and 17 years of age compared with the population ≥18 years of age (73.5% vs. 68.8%). The therapeutic level was exceeded less frequently in the population between 3 and 17 years of age despite them being given a significantly higher dose per kilogram of body weight than in the population ≥18 years of age (13.64 mg/kg vs. 10.43 mg/kg, p < 0.0001). Patients ≥18 years of age were statistically significantly more likely to be in the group with a suspected drug overdose (73.9% vs. 26.1%), and suicide attempts only occurred in elderly patients (100.0% vs. 0.0%, p = 0.003). Conclusion: The results of the TDM of CBZ showed that only 71% of all samples were at the therapeutic level. To ensure the maximum efficacy and safety of the therapy, it is necessary to monitor the concentration of CBZ regardless of sex and age.

Verified
Journal Article
Open access
PDF file
ADAnna Dąbrowska
Anna Dąbrowska
EGElżbieta Grześk
Elżbieta Grześk
AUAnna Urbańczyk
Anna Urbańczyk
MMMarta Mazalon
Marta Mazalon
GGGrzegorz Grześk
Grzegorz Grześk
SKSylwia Koltan
Sylwia Koltan
Background and Objectives: Inborn errors of immunity (IEI) refer to genetically determined disorders presenting with recurrent infections, autoimmunity, allergies, and malignancies. IEI is now commonly used, replacing the previously used term primary immunodeficiencies (PID). The 10 warning signs of IEI are widely used in the identification patients with IEI. The aim of the study was to determine and compare the utility of the 10 and 14 warning signs in IEI diagnosing. Methods: A retrospective analysis of 2851 patients was performed (98.17% were subjects under 18 years old and 1.83% were adults). All patients were questioned about the 10 warning signs and four additional signs: severe eczema, allergies, hemato-oncologic disorders and autoimmunity. Sensitivity, specificity, positive and negative predictive values, and odds ratio were calculated for the 10 and 14 warning signs. Results: IEI were diagnosed in a total of 896 (31.4%) patients and excluded in 1955 (68.6%). The strongest predictors of IEI were hemato-oncologic disorders (OR = 11.25; p < 0.001) and autoimmunity (OR = 7.74; p < 0.001). The strongest predictors of severe IEI were hemato-oncologic disorders (OR = 89.26; p < 0.001), positive family history (OR = 25.23; p < 0.001), and autoimmunity (OR = 16.89; p < 0.001). There were 20.4% and 14% of IEI patients without any signs from the 10 and 14 warnings signs, respectively (p < 0.001). 20.3% and 6.8% of patients with severe PIDs had no presence of any signs from 10 and 14 signs, respectively (p = 0.012). Conclusions: The 10 warning signs have limited usefulness in identifying IEI. The modified list of 14 warning signs seems to represent an effective diagnostic method for the detection of IEI patients, especially those with severe PIDs.

25 July 2025 in Molecules
Verified
Journal Article
Open access
PDF file
MSMarlena Stielow
Marlena Stielow
ŁFŁukasz Fijałkowski
Łukasz Fijałkowski
AAAidas Alaburda
Aidas Alaburda
GGGrzegorz Grześk
Grzegorz Grześk
EGElżbieta Grześk
Elżbieta Grześk
Alicja NowaczykAlicja Nowaczyk
Alicja Nowaczyk
Studies have shown that sodium-glucose cotransporter type 2 (SGLT2) inhibitors not only help lower blood glucose levels but also offer cardioprotective effects, reduce the progression of heart failure, and may even slow the progression of aortic stenosis. The mechanisms of these beneficial properties are thought to involve multiple pathways, including reducing inflammation, oxidative stress, and improving cellular energy metabolism. Advancing knowledge about the mechanisms of action of these drugs and their effects on the course of the aforementioned diseases has become the subject of intensive clinical and scientific research. This publication aims to provide insight into the role of SGLT2 inhibitors in the context of diabetes mellitus, heart failure and acute coronary syndrome, through clinical analysis, mechanistic insights and comparison of the effects of these drugs.

15 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
GGGrzegorz Grześk
Grzegorz Grześk
AWAdrianna Witczyńska
Adrianna Witczyńska
MWMagdalena Węglarz
Magdalena Węglarz
ŁWŁukasz Wołowiec
Łukasz Wołowiec
Jacek NowaczykJacek Nowaczyk
Jacek Nowaczyk
Alicja NowaczykAlicja Nowaczyk
Alicja Nowaczyk
Endogenous nitric oxide (NO)-dependent vascular relaxation plays a leading role in the homeostasis of the cardiovascular, pulmonary, and vascular systems and organs, such as the kidneys, brain, and liver. The mechanism of the intracellular action of NO in blood vessels involves the stimulation of the activity of the soluble cytosolic form of guanylyl cyclase (soluble guanylyl cyclase, sGC), increasing the level of cyclic 3′-5′—guanosine monophosphate (cGMP) in smooth muscle and subsequent vasodilation. In recent years, a new group of drugs, soluble guanylyl cyclase stimulators, has found its way into clinical practice. Based on the CHEST-1 and PATENT-1 trials, riociguat was introduced into clinical practice for treating chronic thromboembolic pulmonary hypertension (CTEPH). In January 2021, the FDA approved the use of another drug, vericiguat, for the treatment of heart failure.

1 February 2016 in Pharmacological Reports
Verified
Journal Article
Closed access
EGElżbieta Grześk
Elżbieta Grześk
BMBartosz Malinowski
Bartosz Malinowski
MWMichał Wiciński
Michał Wiciński
KSKatarzyna Szadujkis-Szadurska
Katarzyna Szadujkis-Szadurska
TSThabit A. Sinjab
Thabit A. Sinjab
GGGrzegorz Grześk
Grzegorz Grześk